原发性肺腺癌与配对脑转移瘤的突变谱揭示KRAS突变的重要性
这项单中心回顾性研究对2000至2015年间连续切除的肺腺癌脑转移瘤及配对原发瘤进行基因分型,发现多数驱动改变在脑转移中保留,KRAS突变在原发瘤转移至脑的病例中更常见(32/55,58%),高于TCGA(33%,p<0.005),KRAS G12C最常见(26%患者)且在脑转移中显著富集。
要点
- KRAS突变在原发瘤转移至脑的病例中占58%(32/55),高于TCGA的33%(p<0.005)。
- KRAS G12C最常见(26%患者),KRAS G12C和G13C变异在脑转移中显著富集。
- 多数驱动改变在脑转移中保留,仅7%病例无共享突变。
核心结论
- 结果提示KRAS改变在肺腺癌脑转移的病理生物学中起重要作用。
- 由于选择性靶向KRAS G12C的抑制剂正进入临床,这具有直接的治疗意义。
研究设计与样本
- 单中心回顾性研究,对2000至2015年诊断的连续切除的肺腺癌脑转移瘤及配对原发瘤进行基因分型,使用Ion Torrent Oncomine Comprehensive Cancer Panel v3。
- 444例连续脑转移瘤中210例(49%)起源于肺癌,111例样本分析成功,包括54对脑转移瘤和原发瘤。
主要发现
- 多数驱动改变在脑转移中保留;仅原发瘤、仅脑转移瘤或两部位均有的私有改变分别占22%、26%和26%,7%无共享突变。
- KRAS突变在原发瘤转移至脑的病例中更常见(32/55,58%),高于TCGA(33%,p<0.005),且独立于临床或病理特征。
- 14例显示EGFR信号通路改变,包括脑转移私有的额外KRAS改变。
- KRAS G12C检测最常见(26%患者),KRAS G12C和G13C变异在脑转移中显著富集。
- 同步和异时病例具有相似的突变谱。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brain metastases present a significant complication in lung cancer with an unmet therapeutic need. METHODS: In this single-centre, retrospective study, we genotyped a clinico-pathologically well-annotated cohort of consecutively resected brain metastases of lung adenocarcinomas and paired primary tumours, diagnosed from 2000 to 2015, using the Ion Torrent Oncomine Comprehensive Cancer Panel v3. RESULTS: Among 444 consecutive brain metastases, 210 (49%) originated from lung cancer. Analysis was successful in 111 samples, including 54 pairs of brain metastasis and primary tumour. Most driver alterations were preserved in brain metastases. Private alterations exclusive to primary tumours, brain metastases or both sites (intersecting cases) were present in 22%, 26% and 26% of cases, respectively. Seven percent had no shared mutations. KRAS mutations were more frequent in primary tumours metastasised to the brain (32/55, 58%) compared to TCGA (33%, p < 0.005) and own data from routine diagnostics, independent from clinical or pathological characteristics. Fourteen cases showed alterations in the EGFR signalling pathway including additional KRAS alterations that were private to brain metastases. KRAS G12C was detected most frequently (26% of patients) and KRAS G12C and G13C variants were significantly enriched in brain metastases. Synchronous and metachronous cases had a similar mutation profile. CONCLUSIONS: Our results suggest an important role of KRAS alterations in the pathobiology of brain metastases from lung adenocarcinomas. This has direct therapeutic implications as inhibitors selectively targeting KRAS G12C are entering the clinics.
引用
- Vassella E, Kashani E, Zens P, et al. Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations. Eur J Cancer. 2021. PMID: 34781171. doi:10.1016/j.ejca.2021.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。